using the link I pasted above, https://c19study.com/, the first 9 (out of many studies shown (about 44 back to the start of May, almost all positive)...shown below quoted and abridged for clarity:
Global HCQ studies. PrEP, PEP, and early treatment studies show high effectiveness, while late treatment shows mixed results.
*7/3 Positive Lancent Rheumatology, (Peer Reviewed) COVID-19 in patients with rheumatic disease in Hubei province, China:
Rheumatic disease patients on HCQ had a lower risk of COVID-19 than those on other disease-modifying anti-rheumatic drugs,
7/3 Positive Scholz et al., COVID-19 Outpatients – Early Risk-Stratified Treatment with Zinc Plus Low Dose Hydroxychloroquine and Azithromycin:
Early treatment with HCQ+AZ+Z results in 84% lower hospitalization and 80% lower death. No cardiac side effects. Retrospective 518 patients (141 treated, 377 control).
7/1 Positive Arshad et al. (Peer Reviewed) Treatment with Hydroxychloroquine, Azithromycin, and Combination in Patients Hospitalized with COVID-19
HCQ decreases mortality from 26.4% to 13.5% (HCQ) or 20.1% (HCQ+AZ). Michigan 2,541 patients retrospective. Differences in age and sex between HCQ and untreated groups may favor the treatment and the control respectively.
6/30 Positive Mikami et al. (Peer Reviewed) Risk Factors for Mortality in Patients with COVID-19 in New York City
HCQ decreases mortality, Retrospective 6,000 patients in New York City.
6/29 Positive Ferreira et al., (Preprint) Chronic treatment with hydroxychloroquine provides protection against COVID, ...the actual benefit may be significantly higher .
6/25 Positive Lagier et al. Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France:
Early treatment leads to significantly better clinical outcome and faster viral load reduction. Retrospective 3,737 patients.
6/22 In Vitro Wang et al. (not included in the study count) Chloroquine and hydroxychloroquine as ACE2 blockers to inhibit viropexis of COVID-19
6/22 Positive Chen et al. (Preprint) Efficacy and safety of chloroquine or hydroxychloroquine in moderate type of COVID-19: a prospective open-label randomized controlled study......Significantly faster clinical recovery and shorter time to RNA negative (from 7.0 days to 2.0 days (HCQ), 67 patients with mild/moderate cases.
6/19 Positive (news) SMSH Sawai Man Singh Hospital, India (not included in the study count) HCQ beneficial as preventive drug: SMS doctors told ICMR
PrEP with 4,300 very high risk healthcare workers in a hospital with up to 500+ COVID patients at a time, only 1% cases, all recovered.*